Showing 1,581 - 1,600 results of 101,259 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((fold decrease) OR (mean decrease)) ))', query time: 1.59s Refine Results
  1. 1581
  2. 1582
  3. 1583
  4. 1584
  5. 1585

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  6. 1586
  7. 1587

    Effects of T5-1 and T5-12 on TAS2R5 expression during protein synthesis inhibition. by Donghwa Kim (252081)

    Published 2025
    “…In the presence of CHX, T5-1 caused a decrease in receptor expression with the prolonged exposure, while T5-12 exposure had no significant effect on expression. * , P < 0.01 vs vehicle control.…”
  8. 1588
  9. 1589
  10. 1590
  11. 1591
  12. 1592
  13. 1593
  14. 1594
  15. 1595
  16. 1596
  17. 1597
  18. 1598
  19. 1599
  20. 1600